Doconexent
- Generic Name
- Doconexent
- Brand Names
- Animi-3 With Vitamin D, Citranatal Harmony
- Drug Type
- Small Molecule
- Chemical Formula
- C22H32O2
- CAS Number
- 6217-54-5
- Unique Ingredient Identifier
- ZAD9OKH9JC
- Background
A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic acid or commercially manufactured from microalgae. It is an omega-3 fatty acid and primary structural component of the human brain, cerebral cortex, skin, and retina thus plays an important role in their development and function. The amino-phospholipid DHA is found at a high concentration across several brain subcellular fractions, including nerve terminals, microsomes, synaptic vesicles, and synaptosomal plasma membranes .
- Indication
Used as a high-docosahexaenoic acid (DHA) oral supplement.
- Associated Conditions
- Fredrickson classification type IV Hyperlipidemia, Fredrickson type IIb hyperlipidemia, Type III hyperlipidaemia
- Associated Therapies
- Nutritional supplementation
Differential Thrombogenesis by EPA and DHA Mediated by HDL
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- The Miriam Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06494488
Docosahexaenoic Acid on Breath Holding Spells in Children
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 60
- Registration Number
- NCT03965988
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
DHA Brain Delivery Trial
- Conditions
- Brain DHA Delivery and Alzheimer's Disease Risk
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 365
- Registration Number
- NCT03613844
- Locations
- 🇺🇸
USC Keck School of Medicine, Los Angeles, California, United States
Docosahexaenoic Acid (DHA) Supplementation in Amblyopia
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT03402789
- Locations
- 🇺🇸
Johns Hopkins Hospital, Wilmer Eye Institute, Baltimore, Maryland, United States
Dose-Finding Study of SC411 in Children With Sickle Cell Disease
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Micelle BioPharma Inc
- Target Recruit Count
- 68
- Registration Number
- NCT02973360
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Children's Healthcare of Atlanta - Emory University, Atlanta, Georgia, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 10
- Registration Number
- NCT02690857
P. Falciparum Resistance to Artemisinin in Vietnam
- Conditions
- Drug Resistant Malaria Due to Plasmodium Falciparum
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- National Institute of Malariology, Parasitology and Entomology, Vietnam
- Target Recruit Count
- 120
- Registration Number
- NCT02604966
- Locations
- 🇻🇳
Chu R Cam commune, Pleiku, Gialai, Vietnam
A Sickle CEll Disease ComplicatioN Trial
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- Micelle BioPharma Inc
- Target Recruit Count
- 210
- Registration Number
- NCT02604368
Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Carol Fabian, MD
- Target Recruit Count
- 24
- Registration Number
- NCT02517502
- Locations
- 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Kansas University DHA Outcome Study (KUDOS) Follow-Up
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Susan Carlson, PhD
- Target Recruit Count
- 190
- Registration Number
- NCT02487771
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.